# Vor Biopharma Inc. (VOR) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $25.05, market value $1.5 billion.

## Valuation
- **P/E (trailing): 0.1×**. Vor Biopharma Inc. trades at 0.1× trailing earnings. The Healthcare median in the September 2026 study was 28.5×.
- **Free-cash-flow yield: -9.5%** (5-yr avg -72.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.
- **Earnings yield: 721.3%**. The inverse of the P/E: 721.3% of the price is earned each year.

## Profitability
- **Return on equity: 423.6%**. A 423.6% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -107.2%**. Earnings per share fell 107.2%.

## Financial health
- **Current ratio: 18.20** (quick 18.20). Current assets cover the next year's liabilities 18.20 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Vor Biopharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (8 analysts). 8 analysts cover Vor Biopharma Inc.; the consensus is strong_buy, with an average price target of $39.00 (+56% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -35.1%** (YTD 91.5%, 3-mo 90.3%). The shares are down 35.1% over twelve months including dividends.
- **From 52-week high: -49.8%** (285.4% above the low). Trading 50% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 64**. An RSI of 64 is neutral.
- **Beta (1 yr): 1.34** (volatility 113%). Beta of 1.34 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=VOR · Page: https://foliofundamentals.com/stocks/vor

Not investment advice.